FORMULATION ARTICLES

FORMULATION VIDEOS

Learn more about five key factors for advancing targeted in vivo LNP programs, from formulation and targeting strategies to bioanalytical readiness and scalability.

In this clip, Sanofi’s Greg Troiano kickstarts our discussion on some of the advances he’s seen in the supply chain for linear mRNA-LNP products, both in terms of supply availability and supplier capability.

Optimize your LNP research with KNAUER's innovative software. Streamline your workflow, overcome challenges, and achieve optimal results with ease.

As the RNA-LNP space continues to diversify beyond linear mRNA and infectious disease vaccines, Kate Zhang of Hopewell Therapeutics, Sumit Luthra of Sanofi, and Ben Muir of BioNTech each address several misconceptions about LNP composition today and how the rise of novel RNA modalities, more advanced mechanisms of action, and novel lipids are challenging our understanding of/work with LNPs today.

ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS